Ibrance palbociclib: Phase III data

Top-line data from the double-blind, international Phase III PALOMA-2 trial in 666 postmenopausal women with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer showed that first-line treatment with once-daily 125 mg oral Ibrance for the first 3 weeks of each 4-week cycle plus letrozole met the primary endpoint of improving PFS vs. placebo plus letrozole. Pfizer plans to present detailed PALOMA-2 data at the American Society of Clinical Oncology meeting in Chicago in June. ...